Skip to Content

SHARE

Clinical Trials Details

Myelodysplastic and Acute Myeloid Leukemia Registry

Connect, The Myelodysplastic Syndromes (MDS), and Acute Myeloid Leukemia (AML) Disease Registry

Objective

Patients newly diagnosed (within 60 days prior to enrollment) with confirmed, primary or secondary MDS or AML will be eligible to participate.  This is a prospective, longitudinal multi-center observational study.

IRB Protocol Number
NA
Principal Investigator(s)
Brock Whittenberger, MD
Sponsor(s)
Celgene Corporation
Contact
Linda Allen, RN OCN at 406-435-7481
or lallen@billingsclinic.org

Location

  • Billings Clinic Hospital Fountain Courtyard - South of the Hospital Cafeteria
    2750 9th Ave North
    Billings, MT 59101